Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1093335 | 1.00 | HPGD (0.49) | HPGDL3MBTL1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL29415928 | 1.00 | HPGD (0.49) | HPGDL3MBTL1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL1093334 | 1.00 | HPGD (0.49) | HPGDL3MBTL1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL31041390 | 0.89 | LMNA (0.44) | HPGDL3MBTL1KDM4ESMN1; SMN2HTT | |
| SCHEMBL2459611 | 0.87 | L3MBTL1 (0.44) | HPGDL3MBTL1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL2459612 | 0.87 | L3MBTL1 (0.44) | HPGDL3MBTL1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL14012246 | 0.82 | L3MBTL1 (0.41) | HPGDL3MBTL1MAPTSMN1; SMN2RAB9A | |
| SCHEMBL4912110 | 0.80 | TSHR (0.43) | L3MBTL1KDM4ELMNACHRM2HTR1A | |
| SCHEMBL3371008 | 0.72 | GAA (0.38) | L3MBTL1MAPTSMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL20848093 | 0.72 | GAA (0.38) | L3MBTL1MAPTSMN1; SMN2RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136315-B2 | CXCR2 antagonist | MEDSHINE DISCOVERY INC. (CN) | 2021-10-05 | — | — | US | disclosed |
| EP-3738956-A1 | CXCR2 ANTAGONIST | Medshine Discovery Inc. (CN) | 2020-11-18 | — | — | EP | disclosed |
| US-20200339549-A1 | CXCR2 ANTAGONIST | Shenzhen Optimum Biological Technology Co., Ltd (CN) | 2020-10-29 | — | — | US | disclosed |
| US-7452994-B2 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED, INC. (CA) | 2008-11-18 | — | — | US | disclosed |
| US-7452994-B2 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED, INC. (CA) | 2008-11-18 | — | — | US | disclosed |
| US-20070060757-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED INC. (CA) | 2007-03-15 | — | — | US | disclosed |
| US-20070060757-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED INC. (CA) | 2007-03-15 | — | — | US | disclosed |
| US-5789587-A | Heterocyclic-fused lactams promote release of growth hormone | MERCK & CO., INC. (US) | 1998-08-04 | — | — | US | disclosed |
| US-5606054-A | Heterocyclic-fused lactams promote release of growth hormone | MERCK & CO., INC. (US) | 1997-02-25 | — | — | US | disclosed |
| WO-1995016692-A1 | HETEROCYCLIC-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1995-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060757-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | CBR1, POR, CBR3 | HPGD 362/4885L3MBTL1 4592/4885KDM4E 1442/4885 |
| US-11136315-B2 | CXCR2 antagonist | CXCR2, CXCR3, CXCR1 | HPGD 416/4885L3MBTL1 4389/4885KDM4E 4494/4885 |
| US-20200339549-A1 | CXCR2 ANTAGONIST | CXCR2, CXCR3, CXCR1 | HPGD 416/4885L3MBTL1 4389/4885KDM4E 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.